Plain-English translation of NCT04366518 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called Rivastigmine can help reduce auditory hallucinations—hearing voices that aren't there—in people with psychosis. About one-third of people with psychosis don't respond well to standard antipsychotic medications, so researchers are exploring whether this medication might work differently to help these voices go away. The study also includes healthy volunteers to help understand how the brain processes sound and perception.
Hearing voices is one of the most distressing and dangerous symptoms of psychosis, and current medications don't work for everyone. By understanding how the brain creates these false perceptions, researchers hope to develop new, better treatments based on how the brain actually works.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will visit the research clinic where researchers will give you either the study medication or a placebo (an inactive pill that looks the same). You'll also complete brain imaging scans and perception tests to help researchers understand how your brain processes sound. The study involves multiple visits over several weeks, and researchers will carefully monitor your health and symptoms throughout.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States